Cooperative Agreement UG3CA290364
Award Date
7/9/25
Completion Date
6/30/28
Dollars Obligated
$398K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Cooperative Agreement
Place of Performance
New York, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $778,873 to Cold Spring Harbor Laboratory (CSHL) to investigate the role of the SOAT1 enzyme as a therapeutic target for pancreatic ductal adenocarcinoma (PDAC). The key objectives are to: 1) Use genetically engineered mouse models to test the effects of SOAT1 deletion on PDAC development and metastasis, and characterize the metabolic impacts; 2) Develop first-in-class small...
The National Cancer Institute (NCI) awarded a $737,444 Cooperative Agreement under the Cancer Cause and Prevention Research (CFDA 93.393) program to the University of Hawaii to conduct research aimed at "Uncovering Causal Protein Markers to Characterize Pancreatic Cancer Etiology and Improve Risk Prediction." The project seeks to: 1) identify putative causal protein biomarkers for pancreatic ductal adenocarcinoma (PDAC) risk using novel research methods; 2) functionally characterize...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $667,118.00 to The Regents of the University of California, San Francisco to conduct research aimed at "Identifying and Disabling New Pathways for Macromolecular Recycling in Pancreatic Cancer". The 5-year project, beginning on April 1, 2025, will systematically analyze pancreatic cancer cell lysosomes to identify key proteins that enable pro-survival catabolic...
The National Cancer Institute (NCI) awarded a $159,540 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the University of North Carolina at Chapel Hill. The grant supports research to mechanistically examine and inhibitor target nutrient scavenging processes, including macropinocytosis and autophagy, for the treatment of pancreatic cancer. The research aims to understand how inhibitors of the KRAS-ERK MAPK pathway regulate these metabolic processes over time, and...
The National Cancer Institute (NCI) awarded a $581,381 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the Sloan-Kettering Institute for Cancer Research. The 5-year grant, effective June 5, 2025, will fund research to investigate the role of microhomology-mediated end-joining (MMEJ) in mitosis and its impact on drug resistance in cancer. The key products of this research will be a better understanding of DNA damage repair pathways and how they contribute...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $269,280 to Cold Spring Harbor Laboratory to conduct research on a novel targeted approach for treating K-RAS(G12C) mutation-driven cancers. The research aims to develop prodrug molecules that can selectively degrade the K-RAS(G12C) oncogenic protein while simultaneously releasing cytotoxic natural products to target multiple cancer pathways. Key objectives include determining the...
This federal Project Grant award of $269,280 from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), supports research to determine the biological effects and antitumor activity of a senescent cell-targeted antibody, SIWA318, in preclinical models of pancreatic ductal adenocarcinoma (PDAC). The research aims to evaluate whether depletion of senescent and pro-fibrotic cells in the PDAC tumor microenvironment can improve the efficacy of standard-of-care...
This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) provides $113,203 to the University of Chicago to investigate the immunomodulatory effects of a dietary compound called Sumiki's Acid (SKA) on natural killer (NK) cells for cancer immunoprevention. The research aims to determine SKA's potential as a cancer-preventive agent, elucidate its underlying molecular mechanisms, and explore medicinal chemistry and bioengineering approaches to...
The National Cancer Institute (NCI) awarded a $616,495 Project Grant under CFDA 93.396 - Cancer Biology Research to The University of Texas MD Anderson Cancer Center. The grant supports research to define the biological role of sulfatide in the development and progression of pancreatic cancer precursor lesions, test whether inhibition of sulfatide metabolism is a viable cancer interception strategy, and conduct a proof-of-concept study using mass spectrometry imaging to identify positive margins...
The National Cancer Institute (NCI) awarded a $154,642 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Sloan-Kettering Institute for Cancer Research. The grant, titled "Targeting the Evolving Immunopeptidome of Metastatic Colorectal Cancer," aims to systematically elucidate the evolving immunopeptidome from normal colon, primary tumor, and metastatic lesion patient-derived organoids (PDOs) through mass spectrometry. This will identify conserved...